Abstract
Dysregulation of the epidermal growth factor receptor (EGFR) signaling pathway is associated with the development and progression of malignancy, and EGFR-targeted therapies offer the promise of better treatment for many types of solid tumors, including non-small cell lung cancer. Anti-EGFR agents include monoclonal antibodies (mAbs) targeting the EGFR extracellular receptor domain and small-molecule tyrosine kinase inhibitors (TKIs) targeting the EGFR intracellular kinase domain. Both mAbs and TKIs have demonstrated encouraging results as monotherapies and in combination with chemotherapy and radiotherapy. This review provides a critical update on the status of these novel therapeutics.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / metabolism*
-
Clinical Trials as Topic
-
Disease Progression
-
Enzyme Inhibitors / therapeutic use
-
Gene Expression Regulation, Neoplastic / drug effects
-
Genes, erbB-1 / drug effects
-
Genes, erbB-1 / genetics*
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / metabolism*
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Signal Transduction / drug effects
-
Vascular Endothelial Growth Factor A / drug effects
-
Vascular Endothelial Growth Factor A / genetics
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Vascular Endothelial Growth Factor A
-
Protein-Tyrosine Kinases